Riding the Early Adoption Wave Created by Ferring’s Rebyota, Aimmune’s Vowst, is Set to Provide a New Fecal Microbiota Transplant (FMT) Option for Patients Struggling with Recurrent Clostridioides Difficile, According to Spherix Global Insights
Ferring Pharmaceutical’s achieved an innovative milestone in C.Diff treatment when it launched Rebyota, the first FDA approved Fecal Microbiota Transplant (FMT) therapy, earlier this year EXTON, Pa., May 22, 2023 — Prior to Ferring Pharmaceuticals’ Rebyota, physicians interested in using fecal microbiota transplants (FMT) to treat patients with recurrent clostridioides difficile (C.Diff) had to turn […]
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on the […]
Approximately One Year Post-Launch, AbbVie’s Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s disease market. EXTON, Pa., May 17, 2023 /PRNewswire/ — In March of 2022, the FDA approved AbbVie’s JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC). Of note, however, JAK […]
New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological agents to disrupt the market EXTON, Pa., May 8, 2023 /PRNewswire/ — According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type […]
Over Three Years After Receiving a Complete Response Letter From the FDA, Takeda’s Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4, 2023 – In December 2019, Takeda Pharmaceutical Company (“Takeda”) announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) […]
Ferring Pharmaceuticals’ 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights
Aimmune/Seres’ SER-109 poised to challenge first to market Ferring’s Rebyota for treatment of clostridioides difficile Exton, PA., March 17, 2023 – When the FDA approved Rebyota, a new class of clostridioides difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant breakthrough doctors treating the disease have seen in years. Rebyota falls in the class […]
Introduction of AstraZeneca’s Saphnelo (anifrolumab) has Expanded the Use of Biologic Agents in the Treatment of Systemic Lupus Erythematosus (SLE), Resulting in Gains for GSK’s Benlysta (belimumab) as Well, According to Spherix Global Insights
Latest Saphnelo launch tracking data from Spherix showcases rheumatologists’ shifting perception on the drug’s steroid-sparing capabilities yet highlights access barriers hindering use. EXTON, Pa., February 22, 2023 – Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease and few effective treatment options. However, after […]
